Trial Profile
A Single Center, Randomized, Double-Blind, Crossover Study to Assess Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of BTDS and Ketoconazole, Used As a CYP3A4 Inhibitor, in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary) ; Ketoconazole (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Purdue Pharma
- 03 Jan 2013 New trial record